Pharvaris (NASDAQ:PHVS - Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, April 9th. Analysts expect Pharvaris to post earnings of ($0.74) per share for the quarter.
Pharvaris Price Performance
PHVS stock traded down $0.34 during trading on Friday, reaching $14.28. 19,107 shares of the company were exchanged, compared to its average volume of 71,863. The company has a market capitalization of $746.70 million, a price-to-earnings ratio of -5.10 and a beta of -3.02. The company has a 50-day moving average of $16.40 and a two-hundred day moving average of $18.77. Pharvaris has a twelve month low of $13.16 and a twelve month high of $25.50.
Wall Street Analysts Forecast Growth
Separately, JMP Securities raised their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
Check Out Our Latest Analysis on PHVS
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
